S. Korea Ministry Denies Bayer Schering Label Of Ineptitude In R&D Plans
This article was originally published in PharmAsia News
South Korea's Health Ministry denies it blundered and lost out as the site of Bayer Schering Pharma's research and development center to be built instead in China. The firm's Asia-Pacific chief, Chris Lee, had told South Korean reporters the country lost because of government ineptitude, including misdirected or unanswered telephone calls while the company was considering South Korea as the site. But the Ministry of Health, Welfare and Family Affairs said it was never contacted by Bayer Schering about such a move. Since that denial, the company has declined to comment, claiming business confidentiality. (Click here for more
You may also be interested in...
Royal Philips will make 43,000 medical ventilators by year-end for use in the US and make 2,500 more for the Strategic National Stockpile in a deal with the US government worth $646.7m. See what Philips’ CEO Frans van Houten said about it here.
Pharma manufacturing is operating well below normal levels in India, disrupted by labor absenteeism and supply chain issues amid the ongoing lock-down in the country, though the government is actively engaged in addressing bottlenecks. A speedy recovery is vital not just for domestic supplies.
Moderna is pursuing a single-antigen strategy even though some of its mRNA vaccines have included multiple antigens; the SARS-CoV-2 spike protein likely provides the best antigen for developing immunity against the virus.